Study time periods.
figure
posted on 2024-03-22, 17:36 authored by Alan J. M. Brnabic, Sarah E. Curtis, Joseph A. Johnston, Albert Lo, Anthony J. Zagar, Ilya Lipkovich, Zbigniew Kadziola, Megan H. Murray, Timothy RyanDMT, disease-modifying therapy; MS, multiple sclerosis; PDC, proportion of days covered.
(TIF)
History
Usage metrics
Categories
Keywords
xlink "> researcherstype 2 diabetesrestricted hazard ratiorelated factor 2provide human validationnovel treatment pathwaysinnovative statistical methodologydetermine whether treatmentfour treatment cohortsderive four cohortselectronic healthcare datainform drug developmentdimethyl fumarate versusdimethyl fumarate towardsteriflunomide &# 8211study effectively demonstratedchronic kidney diseasedimethyl fumaratetwo cohortsworld datadrug repurposingdrug discoverystatistically significantmultiple sclerosismodifying therapiesmachine learningjanuary 2013individual outcomesindividual outcomeglatiramer acetatefirst occurrencedefinitively supportdecember 2018confidence intervalcomposite endpointcardiovascular disease97 ])90 ])86 ]).
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC